Physician profile
Anat Lebow
NPI 1831211226
$9,114.75
in general payments reported to CMS, 2019-2025
22 companies · $3,643 in 2025
The $3,643 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $186 · 2021: $348 · 2022: $557 · 2023: $1,114 · 2024: $2,715 · 2025: $3,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,398 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,397.58 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,651.38 | 2022-2025 | |
| Genzyme Corporation | $1,502.68 | 2022-2025 | |
| Galderma Laboratories, L.P. | $1,205.87 | 2019-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $847.79 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $571.04 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $543.40 | 2022-2025 | Anzupgo, Adbry |
| Pfizer INC. | $423.28 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $399.18 | 2024-2025 | |
| Ucb, INC. | $347.62 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $336.91 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $247.09 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $241.25 | 2023-2025 | Taltz, Ebglyss, Zepbound |
| Arcutis Biotherapeutics, INC. | $200.91 | 2023-2025 | Zoryve |
| Epi Health, LLC | $158.73 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $146.69 | 2022-2025 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $107.00 | 2023-2025 | Winlevi, Absorica Ld |
| Allergan, INC. | $70.36 | 2020-2022 | |
| Organon LLC | $29.79 | 2025 | |
| Dermavant Sciences, INC. | $25.44 | 2023 | Vtama |
| Almirall LLC | $25.00 | 2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.77 | 2023 | Jublia |
| Journey Medical Corporation | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anat Lebow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.